Fed. Circ. Snubs Amgen Bid For More Info On Pfizer Biosimilar
The Federal Circuit on Thursday shot down Amgen Inc.'s bid to squeeze more information out of Pfizer Inc. about a proposed biosimilar of anemia drug Epogen, finding that Amgen doesn't need...To view the full article, register now.
Already a subscriber? Click here to view full article